Rita Jain

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Hampton, NJ
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Ajim Tamboli, Attorney-in-Fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Rita Jain

Form 4 holding Director

ANAPTYSBIO, INC

Security class
Restricted Stock Unit
Shares / value
4,000
Estimated value
$92,259
Report date
06 Jan 2026
Price
$15.30
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Avalo Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
1,339
Estimated value
$15,373
Report date
31 Mar 2026
Price
$14.74
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

First Tracks Biotherapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
42,000
Estimated value
Report date
12 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Celldex Therapeutics, Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
16,500
Estimated value
Report date
13 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

First Tracks Biotherapeutics, Inc.

Security class
Restricted Stock Unit
Shares / value
15,000
Estimated value
Report date
12 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ANAPTYSBIO, INC

Security class
Stock Option (right to buy)
Shares / value
5,500
Estimated value
Report date
06 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP, Chief Medical Officer, Director

ChemoCentryx, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
20 Oct 2022
Price
$50.95
Ownership
Direct
Form 4 holding EVP, Chief Medical Officer, Director

ChemoCentryx, Inc.

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
Report date
20 Oct 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP, Chief Medical Officer, Director

ChemoCentryx, Inc.

Security class
Stock Option
Shares / value
0
Estimated value
Report date
20 Oct 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Provention Bio, Inc.

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
27 Apr 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Rita Jain

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .